Odyssey Therapeutics
Odyssey Therapeutics, Inc.
Odyssey Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for autoimmune and inflammatory diseases. The company's strategy involves targeting upstream signaling nodes in the innate immune system to prevent pathological inflammation before it starts, aiming to induce long-lasting remission for patients.
Products & Team
Transcription Factor Therapies Program
In a strategic collaboration with Terray Therapeutics, Odyssey is co-developing first-in-class transcription factor therapies. This program combines Odyssey's expertise in immunology and transcription factor biology with Terray's AI-powered drug discovery platform, tNova, to discover and develop small molecule medicines.
This program aims to address the root causes of inflammatory diseases by creating novel small molecule drugs against specific transcription factor targets, with the potential to treat a wide range of conditions.
Current standard-of-care treatments are often insufficient, failing to provide deep and durable remission for many patients suffering from chronic inflammatory and autoimmune conditions.